Xarelto is a relatively new type of blood-thinning medication in a class of drugs called New Oral Anticoagulants (NOACs). Xarelto is manufactured by Bayer AG and sold in the United States with Bayer’s marketing partner, Janssen Pharmaceuticals. Janssen is a subsidiary of Johnson & Johnson. These companies market Xarelto for…
Philadelphia flyers Defenseman, Kimmo Timonen hopes to recover from a serious clotting disorder to a point, which will allow him to get back on the ice. According to a recent news article from Courier-Post, Timonen has been unable to play this season after being diagnosed with blood clots in his…
One of the main ways drug companies get patients to take their drugs is through direct marketing to potential patients through television, Internet, and magazine advertisements. There was a time when the United States Food and Drug Administration (FDA) did not allow drug companies to direct market to individual users,…
It is hard to watch TV these days without seeing ads for Xarelto. Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs). Other members of this class include Eliquis and Pradaxa. Xarelto is the brand name in the United States for rivaroxaban manufactured by…
New drugs can yield billions of dollars for pharmaceutical companies. Because it takes many years to develop a drug, undergo clinical trials, and get it to market, drug companies will do virtually anything to get as much profit as possible for each new drug. This is especially true when considering…
Xarelto is a member of a class of drugs known as New Oral Anticoagulants (NOACs), along with Eliquis, and Pradaxa. These drugs were designed to replace older blood-thinning drugs such as warfarin, which requires frequent monitoring of a patient’s blood to prevent dangerous side effects. The problem with Xarelto and…
Xarelto is a member of class of drugs known as New Oral Anticoagulants (NOACs) and has been the subject of many recent dangerous drug lawsuits. The makers of Xarelto (Bayer AG and Johnson & Johnson) produced a drug linked to serious clotting disorders, internal bleeding, and intracranial bleeding. Patients were…
Xarelto is a member of a new class of anticoagulant drugs that has been approved to reduce the risk of stroke and other blood-clotting disorders in patients with atrial fibrillation. The new drug, manufactured by Janssen, has been linked to cases of serious internal bleeding disorders, including hemorrhaging and intracranial…
As our Xarelto attorneys have discussed on other blog entries, Johnson and Johnson, Bayer, U.S., and German drugmakers involved with the production and marketing of the drug are performing new studies to increase the profit potential for their flagship anticoagulant. According to a recent article from The Wall Street Journal,…
A recent article in The New York Times examines the risks of Pradaxa. Pradaxa, like Xarelto, is among a relatively new class of blood-thinning drugs turning huge profits for the manufacturer. Patients who had been taking Warfarin, the traditionally prescribed medication to aid in the prevention of strokes, needed to…